Brian W. Ogilvie

GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

Brian W. Ogilvie, Donglu Zhang, Wenying Li et al. · Drug Metabolism and Disposition · 2005 · 326 citations

Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters

Lydia M.M. Vermeer, Caleb D. Isringhausen, Brian W. Ogilvie et al. · Drug Metabolism and Disposition · 2015 · 114 citations

The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel

Brian W. Ogilvie, Phyllis Yerino, Faraz Kazmi et al. · Drug Metabolism and Disposition · 2011 · 105 citations

Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments

Takao Watanabe, Hiroyuki Kusuhara, Tomoko Watanabe et al. · Drug Metabolism and Disposition · 2011 · 99 citations

An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes

Andrew Parkinson, Faraz Kazmi, David B. Buckley et al. · Drug Metabolism and Disposition · 2011 · 70 citations